Source of information | What is the information? | How can it be used? |
---|---|---|
Update of prior systematic review | Utility estimate Nonfatal Intracranial Bleed (severe): 0.1 to 0.51 Nonfatal Intracranial Bleed (moderate): 0.29 to 0.77 Nonfatal Intracranial Bleed (mild): 0.47 to 0.94 Nonfatal Pulmonary Embolism: 0.63 Major Bleed: 0.44 to 0.84 “This result suggested intracranial bleed overall was 2 to 3 times worse than major bleed or pulmonary embolism.” | To help guideline panellists weigh the benefits (absolute reduction in pulmonary embolism) and harms (absolute increase in bleedings). |
Systematic review | Non-utility estimate For the guideline on management of breast lump and primary breast cancer, the systematic review identified one study reporting an additional year in life expectancy or 3% in survival rates were sufficient to make adjuvant chemotherapy worthwhile by 68–84% of women. | To judge to what extent women are willing to accept the burden of adjuvant chemotherapy to benefit from a specific amount of increased survival |
Systematic review | Qualitative finding “Evidence from qualitative studies suggested women may fear screening and may have a high level of anxiety related to colposcopy or treatment.” | To suggest what are the views of local women on cervical cancer screening tests in relation to its psychological impact |
Panel members (either physicians or patients) | Panellists experience In some guideline topics, patient inputs corroborated the panel’s perception. | To serve as complementary sources in addition to the information from systematic review. |